SE0001330L - Novel method of treatment - Google Patents

Novel method of treatment

Info

Publication number
SE0001330L
SE0001330L SE0001330A SE0001330A SE0001330L SE 0001330 L SE0001330 L SE 0001330L SE 0001330 A SE0001330 A SE 0001330A SE 0001330 A SE0001330 A SE 0001330A SE 0001330 L SE0001330 L SE 0001330L
Authority
SE
Sweden
Prior art keywords
treatment
novel method
amoxycillin
treated
image
Prior art date
Application number
SE0001330A
Other languages
English (en)
Other versions
SE0001330D0 (sv
Inventor
Kevin Storm
Creighton Conley
John Roush
Original Assignee
Beecham Pharm Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27383840&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SE0001330(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Beecham Pharm Pte Ltd filed Critical Beecham Pharm Pte Ltd
Publication of SE0001330D0 publication Critical patent/SE0001330D0/sv
Publication of SE0001330L publication Critical patent/SE0001330L/sv

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/429Thiazoles condensed with heterocyclic ring systems
    • A61K31/43Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/424Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/286Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02Local antiseptics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Peptides Or Proteins (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
SE0001330A 1999-04-13 2000-04-11 Novel method of treatment SE0001330L (sv)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12907499P 1999-04-13 1999-04-13
US15072799P 1999-08-25 1999-08-25
US15981399P 1999-10-15 1999-10-15

Publications (2)

Publication Number Publication Date
SE0001330D0 SE0001330D0 (sv) 2000-04-11
SE0001330L true SE0001330L (sv) 2000-10-14

Family

ID=27383840

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0001330A SE0001330L (sv) 1999-04-13 2000-04-11 Novel method of treatment

Country Status (45)

Country Link
EP (4) EP1044680B1 (sv)
JP (2) JP4880125B2 (sv)
KR (1) KR100634937B1 (sv)
CN (1) CN100382782C (sv)
AP (1) AP1806A (sv)
AR (1) AR031068A1 (sv)
AT (2) AT4327U1 (sv)
AU (1) AU767177B2 (sv)
BE (2) BE1013309A5 (sv)
BG (1) BG65006B1 (sv)
BR (1) BRPI0009719B8 (sv)
CA (1) CA2366304C (sv)
CO (1) CO5170471A1 (sv)
CZ (1) CZ298801B6 (sv)
DE (3) DE10017883A1 (sv)
DK (3) DK200000602A (sv)
DZ (1) DZ3150A1 (sv)
EA (1) EA004310B1 (sv)
ES (2) ES2202004T3 (sv)
FI (2) FI20000863A (sv)
FR (1) FR2792198A1 (sv)
GB (1) GB2351661B (sv)
GR (1) GR1003560B (sv)
HK (1) HK1032741A1 (sv)
HU (1) HU229097B1 (sv)
IE (1) IE20000271A1 (sv)
IL (2) IL145580A0 (sv)
IT (1) ITMI20000788A1 (sv)
MA (1) MA25352A1 (sv)
MX (1) MXPA01010377A (sv)
MY (1) MY119953A (sv)
NL (2) NL1014915C2 (sv)
NO (1) NO329694B1 (sv)
NZ (1) NZ514575A (sv)
OA (1) OA11926A (sv)
PE (1) PE20010053A1 (sv)
PL (1) PL197448B1 (sv)
PT (2) PT102450B (sv)
RO (1) RO120817B1 (sv)
SE (1) SE0001330L (sv)
SI (2) SI1044680T1 (sv)
SK (1) SK285140B6 (sv)
TR (1) TR200102963T2 (sv)
TW (1) TWI235067B (sv)
WO (1) WO2000061116A2 (sv)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9407386D0 (en) 1994-04-14 1994-06-08 Smithkline Beecham Plc Pharmaceutical formulation
GB9408117D0 (en) * 1994-04-23 1994-06-15 Smithkline Beecham Corp Pharmaceutical formulations
WO1997009042A1 (en) 1995-09-07 1997-03-13 Smithkline Beecham Corporation Pharmaceutical formulation
SE9802973D0 (sv) 1998-09-03 1998-09-03 Astra Ab Immediate release tablet
US6294199B1 (en) 1999-04-13 2001-09-25 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection comprising administering amoxycillin
US7250176B1 (en) 1999-04-13 2007-07-31 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection
US6878386B1 (en) 1999-04-13 2005-04-12 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection comprising amoxycillin and potassium clavulanate
US6544555B2 (en) 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
US6756057B2 (en) 2000-10-12 2004-06-29 Beecham Pharmaceuticals (Pte) Limited Amoxicillin and potassium clavulanate dosage form
EP1330236A2 (en) * 2000-10-12 2003-07-30 Beecham Pharmaceuticals (Pte) Limited Formulation containing amoxicillin
US20020068078A1 (en) 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
US20030035839A1 (en) * 2001-05-15 2003-02-20 Peirce Management, Llc Pharmaceutical composition for both intraoral and oral administration
CA2452871C (en) 2001-07-06 2011-10-04 Endo Pharmaceuticals, Inc. Oxymorphone controlled release formulations
GB0117618D0 (en) * 2001-07-19 2001-09-12 Phoqus Ltd Pharmaceutical dosage form
US6863901B2 (en) 2001-11-30 2005-03-08 Collegium Pharmaceutical, Inc. Pharmaceutical composition for compressed annular tablet with molded triturate tablet for both intraoral and oral administration
US6827946B2 (en) 2001-12-05 2004-12-07 Collegium Pharmaceutical, Inc. Compositions containing both sedative and non-sedative antihistamines
CA2480826C (fr) 2002-04-09 2012-02-07 Flamel Technologies Formulation pharmaceutique orale sous forme de suspension aqueuse de microcapsules permettant la liberation modifiee de principe(s) actif(s)
JP2005528383A (ja) * 2002-04-10 2005-09-22 ミラー,フレッド,エイチ. 多重相・複数コンパートメントカプセルシステム
US20050042289A1 (en) * 2003-04-29 2005-02-24 Yamanouchi Pharma Technologies, Inc. Tablets and methods for modified release of hydrophylic and other active agents
US8062672B2 (en) 2003-08-12 2011-11-22 Shionogi Inc. Antibiotic product, use and formulation thereof
EP1541129A1 (en) * 2003-12-12 2005-06-15 Cimex AG Pharmaceutical effervescent formulation comprising amoxycillin and clavulanic acid
US20070196396A1 (en) * 2004-02-11 2007-08-23 Rubicon Research Private Limited Controlled release pharmaceutical compositions with improved bioavailability
WO2005099672A1 (en) * 2004-04-13 2005-10-27 Ranbaxy Laboratories Limited A modified release pharmaceutical formulation comprising amoxicillin and clavulanate
EP1880716A1 (en) * 2006-07-19 2008-01-23 Sandoz AG Kit of parts comprising an acid labile and an acid resistant pharmaceutically active ingredient
EP2079453A1 (en) * 2006-10-10 2009-07-22 Penwest Pharmaceuticals Co. Robust sustained release formulations
TR200909787A2 (tr) 2009-12-25 2011-07-21 Bi̇lgi̇ç Mahmut Üçüncü kuşak bir sefalosporin ve klavulanik asit içeren farmasötik formülasyonlar.
TR201000687A1 (tr) 2010-01-29 2011-08-22 Bi̇lgi̇ç Mahmut Aktif madde olarak sefiksim ve klavulanik asit içeren efervesan formülasyonlar
TR201000686A1 (tr) 2010-01-29 2011-08-22 B�Lg�� Mahmut Bakteriyel enfeksiyonların tedavisinde suda çözünebilir sefdinir ve klavulanik asit formülasyonları.@
TR201000688A2 (tr) 2010-01-29 2011-08-22 B�Lg�� Mahmut Aktif madde olarak sefaklor ve klavulanik asit içeren efervesan formülasyonlar.
CA2981759C (en) 2015-04-07 2021-10-12 Church & Dwight Co., Inc. Multicomponent gummy compositions with soft core
CN109394718B (zh) * 2018-11-15 2021-04-27 石药集团中诺药业(石家庄)有限公司 一种阿莫西林分散片及其制备方法
CN110051637A (zh) * 2019-05-21 2019-07-26 葵花药业集团北京药物研究院有限公司 阿莫西林克拉维酸钾制剂及其制备方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0008905B1 (en) * 1978-09-06 1983-02-16 Beecham Group Plc Pharmaceutical compositions containing two beta-lactam derivatives
IL58461A0 (en) * 1978-10-27 1980-01-31 Beecham Group Ltd Intramammary compositions comprising a clavulanic acid salt
FR2470599A1 (fr) * 1979-12-07 1981-06-12 Panoz Donald Perfectionnements apportes aux procedes de preparation de formes galeniques a action retard et a liberation programmee et formes galeniques de medicaments ainsi obtenus
GB9007945D0 (en) * 1990-04-07 1990-06-06 Beecham Group Plc Pharmaceutical formulation
GB9109862D0 (en) * 1991-05-08 1991-07-03 Beecham Lab Sa Pharmaceutical formulations
IT1255522B (it) * 1992-09-24 1995-11-09 Ubaldo Conte Compressa per impiego terapeutico atta a cedere una o piu' sostanze attive con differenti velocita'
EP0680322B1 (en) * 1993-01-22 2000-07-05 Smithkline Beecham Plc Use of clavulanate and an antibacterial compound for the treatment of infections
GB9311030D0 (en) * 1993-05-28 1993-07-14 Smithkline Beecham Corp Pharmaceutical formulations
IL109770A0 (en) * 1993-05-29 1994-11-28 Smithkline Beecham Corp Thermal infusion process for preparing controlled release solid dosage forms of medicaments for oral administration and controlled release solid dosage forms of medicaments prepared thereby
GB9402203D0 (en) * 1994-02-04 1994-03-30 Smithkline Beecham Plc Pharmaceutical formulation
GB9407386D0 (en) * 1994-04-14 1994-06-08 Smithkline Beecham Plc Pharmaceutical formulation
GB9408117D0 (en) * 1994-04-23 1994-06-15 Smithkline Beecham Corp Pharmaceutical formulations
ITMI941169A1 (it) * 1994-06-06 1995-12-06 Smithkline Beecham Farma Formulazioni farmaceutiche
GB9416600D0 (en) * 1994-08-17 1994-10-12 Smithkline Beecham Plc Pharmaceutical formulation
GB9416599D0 (en) * 1994-08-17 1994-10-12 Smithkline Beecham Plc Pharmaceutical formulation
WO1997009042A1 (en) * 1995-09-07 1997-03-13 Smithkline Beecham Corporation Pharmaceutical formulation
GB9616536D0 (en) * 1996-08-06 1996-09-25 Quadrant Holdings Cambridge Co-amoxiclav dosage form
PL334976A1 (en) * 1997-02-14 2000-03-27 Smithkline Beecham Lab Pharmaceutic preparations containing amoxycyclin and clavulate
SK121099A3 (en) * 1997-03-11 2000-06-12 Almag Al Process and apparatus for coating metals
SE9700885D0 (sv) * 1997-03-12 1997-03-12 Astra Ab New pharmaceutical formulation
CN1251035A (zh) * 1997-03-25 2000-04-19 武田药品工业株式会社 胃肠粘膜粘附性药物组合物
JP3746901B2 (ja) * 1997-10-15 2006-02-22 ユニ・チャーム株式会社 開閉自在容器
GB9815532D0 (en) * 1998-07-17 1998-09-16 Lek Pharmaceutical & Cvhemical Pharmaceutical suspension formulation
GB9818927D0 (en) * 1998-08-28 1998-10-21 Smithkline Beecham Plc Pharmaceutical formulation
US6225304B1 (en) * 1999-02-17 2001-05-01 Pharmaceutical Solutions, Inc. Soluble forms of amoxicillin and treatment of animals

Also Published As

Publication number Publication date
JP2011256180A (ja) 2011-12-22
TR200102963T2 (tr) 2002-02-21
FI4823U1 (sv) 2001-02-16
SK285140B6 (sk) 2006-07-07
FIU20000164U0 (sv) 2000-04-11
BRPI0009719B8 (pt) 2021-05-25
BR0009719A (pt) 2002-01-08
BG104329A (en) 2001-11-30
BG65006B1 (bg) 2006-12-29
AT4327U1 (de) 2001-06-25
IL145580A0 (en) 2002-11-10
PE20010053A1 (es) 2001-03-10
ES2202004T3 (es) 2004-04-01
DK200000602A (da) 2000-10-14
NO329694B1 (no) 2010-12-06
EP1269996A1 (en) 2003-01-02
DK1044680T3 (da) 2003-09-29
DE20006626U1 (de) 2000-10-19
DK200000133U3 (da) 2000-07-28
IL145580A (en) 2007-05-15
AR031068A1 (es) 2003-09-10
WO2000061116A3 (en) 2001-02-01
EP1270005A2 (en) 2003-01-02
SK5342000A3 (en) 2000-11-07
SI1044680T1 (en) 2003-12-31
TWI235067B (en) 2005-07-01
FR2792198A1 (fr) 2000-10-20
RO120817B1 (ro) 2006-08-30
EP1270005A3 (en) 2006-05-17
ATE242629T1 (de) 2003-06-15
HK1032741A1 (en) 2001-08-03
PL339591A1 (en) 2000-10-23
MXPA01010377A (es) 2002-10-23
BE1012733A6 (fr) 2001-02-06
PT1044680E (pt) 2003-10-31
EA004310B1 (ru) 2004-02-26
SE0001330D0 (sv) 2000-04-11
KR100634937B1 (ko) 2006-10-17
ES2190692B1 (es) 2004-11-16
BR0009719B1 (pt) 2014-09-30
KR20020015312A (ko) 2002-02-27
GR1003560B (el) 2001-03-16
DE10017883A1 (de) 2000-10-26
NZ514575A (en) 2004-05-28
NO20001870L (no) 2000-10-16
DE60003255T2 (de) 2004-05-06
EP1269997A1 (en) 2003-01-02
MY119953A (en) 2005-08-30
JP2002541187A (ja) 2002-12-03
PT102450A (pt) 2001-02-01
DZ3150A1 (fr) 2000-10-19
BE1013309A5 (fr) 2001-11-06
NL1014915A1 (nl) 2000-10-16
AU767177B2 (en) 2003-11-06
SI20304A (sl) 2001-02-28
FI20000863A0 (sv) 2000-04-11
PL197448B1 (pl) 2008-03-31
ES2190692A1 (es) 2003-08-01
JP4880125B2 (ja) 2012-02-22
HU229097B1 (en) 2013-07-29
CN100382782C (zh) 2008-04-23
AP1806A (en) 2007-12-14
HU0001471D0 (en) 2000-06-28
GB0008923D0 (en) 2000-05-31
NL1014914C1 (nl) 2000-10-16
ITMI20000788A1 (it) 2001-10-11
PT102450B (pt) 2003-09-30
DE60003255D1 (de) 2003-07-17
GB2351661A (en) 2001-01-10
HUP0001471A3 (en) 2001-10-29
CN1382040A (zh) 2002-11-27
OA11926A (en) 2006-04-12
AU5702000A (en) 2000-11-14
CZ298801B6 (cs) 2008-02-06
EA200101075A1 (ru) 2002-04-25
IE20000271A1 (en) 2001-04-04
ITMI20000788A0 (it) 2000-04-11
CA2366304A1 (en) 2000-10-19
CZ20001311A3 (cs) 2000-11-15
NO20001870D0 (no) 2000-04-11
FI20000863A (sv) 2000-10-13
EP1044680B1 (en) 2003-06-11
HUP0001471A2 (en) 2001-03-28
MA25352A1 (fr) 2001-12-31
GB2351661B (en) 2001-10-10
CO5170471A1 (es) 2002-06-27
CA2366304C (en) 2004-06-29
AP2001002284A0 (en) 2001-12-31
NL1014915C2 (nl) 2001-02-12
EP1044680A1 (en) 2000-10-18
WO2000061116A2 (en) 2000-10-19

Similar Documents

Publication Publication Date Title
SE0001330D0 (sv) Novel method of treatment
WO2000061115A3 (en) Pharmaceutical formulation comprising amoxycillin
CO4560547A1 (es) Una forma de dosis de azitromicina y un metodo de trata- miento de una infeccion microbiana que involucra la adminis- tracion de azitromicina
MX9708627A (es) Oxazolidinonas de diazinilo y carbazinilo espirociclicas y biciclicas.
LU91928I2 (fr) Ipilimumab et ses dérivés pharmaceutiquement acceptables (YERVOY®)
DK0871465T3 (da) Anvendelse af ritonavir (ABT-538) til at forbedre farmakokinetikken af lægemidler, som metaboliseres af cytochrom P450, i en metode til behandling af AIDS
ES2180251T3 (es) Comprimido revestido con polimero, que contiene amoxicilina y clavulanato.
GB9917406D0 (en) Compounds
WO2002050061A8 (en) Piperazine derivatives for treatment of bacterial infections
DK0509019T3 (da) Behandling af humane retrovirale infektioner med 2',3'-dideoxyinosin
AU697679B2 (en) Treatment of tinnitis using neuroprotective agents
EP1663959A4 (en) NEW AMIDINE COMPOUNDS FOR THE TREATMENT OF MICROBIAL INFECTIONS
FI96274C (sv) Förfarande för framställning av orala läkemedelsformer av pimobendan
WO2001074788A8 (en) 2-hydroxy-mutilin carbamate derivatives for antibacterial use
DK0748387T3 (da) Fremgangsmåde til isolation af clavulansyre og farmaceutisk acceptable salte deraf fra fermenteringsvæsken af Streptomyces sp. P 6621 FERM P 2804
DE69430385D1 (de) Hiv-proteaseinhibitoren
NO20043445L (no) Kombinasjonsterapi for behandling av bakterielle infeksjoner
DE602004013763D1 (de) Amoxycillin und clavulanat enthaltende pharmazeutische brausefromulierung
ECSP003432A (es) Nuevo metodo de tratamiento
NO890287D0 (no) Fremstilling av beta-laktam-antibiotika.
IT1263076B (it) Uso orale e topico della n-acetil-5-metossitriptamina (melatonina) nella terapia della psoriasi volgare.
MX9605312A (es) Dipsipeptidos ciclicos antifungales.

Legal Events

Date Code Title Description
NAV Patent application has lapsed